We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Vitalife received an FDA warning letter after an inspection revealed violations of the agency’s cGMP rules. The agency also challenged claims made on Vitalife’s website related to three of its products. Read More
The FDA has finalized a rule that will require pharmaceutical companies to electronically submit, list and register information on finished drug products and active pharmaceutical ingredients (APIs) alone or together with one or more other ingredients. Read More
The number of cardiovascular drugs entering the clinical development pipeline has been declining since 1990, according to a study evaluating public data from over 4,000 trials. The decline was seen across Phase I, II, and III clinical trials. Read More
Despite Mylan’s efforts to quell criticism, U.S. lawmakers continue to press the company and the FDA for greater transparency on the cost of the company’s EpiPen epinephrine auto-injector. Read More